摘要
目的评价参附注射液对扩张型心肌病(DCM)伴心力衰竭患者心功能的临床改善及对血浆中脑钠肽(BNP)、血管紧张素Ⅱ(Ang-Ⅱ)、内皮素(ET-Ⅰ)的影响。方法将80例DCM伴心力衰竭患者随机分为对照组和治疗组,每组各40例,对照组给予常规西药治疗,治疗组在西药常规治疗基础上静脉滴注参附注射液50 mL,每日1次,疗程均为2周。观察患者治疗前后临床心功能改善、6分钟步行距离、及血浆中BNP、Ang-Ⅱ、ET-Ⅰ的变化。结果治疗后,治疗组心功能分级、6分钟步行距离改善明显优于对照组(P<0.05)。2组患者血浆中BNP、Ang-Ⅱ、ET-Ⅰ治疗后均较治疗前明显下降,治疗组较对照组下降更明显(P<0.05)。结论参附注射液能够改善DCM伴心力衰竭患者的心功能,且对神经内分泌的激活有干预作用。
Objective To evaluate the clinical efficacy of Shenfu injection on cardiac function of patients with dilated cardiomyopathy （DCM） associated with heart failure （HF） and its influence on brain natriuretic peptide （ BNP）, angiotensinⅡ （ Ang -Ⅱ）, endothelin （ ET - Ⅰ） in plasma. Methods Eighty patients with DCM associated with HF were randomly divided into treatment group （n = 40） and control group （ n = 40）. Patients in the control group were only given conventional treatment of western medicine for two weeks, while patients in the treatment group were treated with Shenfu injection 50 mL on the basis of the conventional treatment for two weeks. The cardiac function, 6 -minute walk test, and the change of BNP, Ang -Ⅱ. ET -Ⅰ were observed before and after treatment. Results The cardiac function and 6 -minute walk test of the Shenfu treatment group improved remarkably compared with control group （ P 〈 0. 05）. The levels of BNP, Ang -Ⅱ, ET -Ⅰ in both groups decreased significantly after treatment （P 〈0. 05）, and that in treatment group decreased more obviously compared with control group （P 〈 0. 05）. Conclusion Shenfu injection can improve cardiac function of patients with DCM associated with HF, which also has therapeutic effects on the activation of neuroendocrine.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2014年第6期478-480,共3页
The Chinese Journal of Clinical Pharmacology
基金
浙江省科技计划基金资助项目(2009C33149)
关键词
参附注射液
心力衰竭
扩张型心肌病
脑钠肽
血管紧张素Ⅱ
内皮素
Shenfu injection
heart failure
dilated cardiomyopathy
brain natriuretic peptide
angiotensin Ⅱ
endothelin
